Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 ...

Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...

Insight On More Than 60 Bispecific Antibody Drug Conjugates In Clinical Trials Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase The mechanism of ...

Restricting step-up dosing and acute triage to a defined T-cell engaging team improves safety and consistency, with patients transitioning back to primary oncologists after stabilization. Standardized ...

Xencor's XmAb819 demonstrated a 25% response rate and 70% disease control in heavily pre-treated ccRCC patients. Read why ...

Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO.

LAS VEGAS, Sept. 15, 2025 /PRNewswire/ -- DelveInsight's Bispecific Antibodies in Oncology Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive ...

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may ...

Bispecific antibodies have emerged as a transformative class of therapies in multiple myeloma and beyond, but the need for ...

We present a bispecific antibody that recognizes an antigen and a hapten and can be applied to various biological assays, including immunoblotting and immunoprecipitation. In immunoblot analysis of ...